Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Johannes Düll"'
Autor:
Viktoria Fuhr, Shanice Heidenreich, Mugdha Srivastava, Angela Riedel, Johannes Düll, Elena Gerhard-Hartmann, Andreas Rosenwald, Hilka Rauert-Wunderlich
Publikováno v:
Cell Death Discovery, Vol 8, Iss 1, Pp 1-9 (2022)
Abstract Altered features of tumor cells acquired across therapy can result in the survival of treatment-resistant clones that may cause minimal residual disease (MRD). Despite the efficacy of ibrutinib in treating relapsed/refractory mantle cell lym
Externí odkaz:
https://doaj.org/article/8bf5573a68b3445a95d06d71c4f572ad
Publikováno v:
Therapeutic Advances in Hematology, Vol 12 (2021)
Patients who relapse or are refractory after first-line therapy for diffuse large B-cell lymphoma (DLBCL) frequently have poor prognoses, especially when they are not candidates for autologous stem cell transplant (ASCT). Tafasitamab is a humanized m
Externí odkaz:
https://doaj.org/article/f9aecf0c913b4afa844ef5d751295c93
Autor:
Alexander M. Leipold, Rudolf A. Werner, Johannes Düll, Pius Jung, Mara John, Emilia Stanojkovska, Xiang Zhou, Hannah Hornburger, Anna Ruckdeschel, Oliver Dietrich, Fabian Imdahl, Tobias Krammer, Stefan Knop, Andreas Rosenwald, Andreas Buck, Leif Erik Sander, Hermann Einsele, K. Martin Kortüm, Antoine-Emmanuel Saliba, Leo Rasche
Publikováno v:
Leukemia. 37:650-658
Pseudo-progression and flare-up phenomena constitute a novel diagnostic challenge in the follow-up of patients treated with immune-oncology drugs. We present a case study on pulmonary flare-up after Idecabtagen Vicleucel (Ide-cel), a BCMA targeting C
Autor:
Stephanie Brändlein, Hermann Einsele, Andreas Rosenwald, Frank Hensel, Deanne L. Greenwood, Johannes Düll, Stefan Knop, Manik Chatterjee, Torsten Steinbrunn, Constantin Lapa, Karin Vanderkerken, Eline Menu, Valentina Dubljevic, Emmanuelle Menoret, Leo Rasche
Purpose: Glucose-regulated protein (GRP) 78 is overexpressed in multiple myeloma, and both its surface expression and its biologic significance as key sensor of the unfolded protein response make GRP78 an ideal candidate for immunotherapeutic interve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6feb903bd6c1d9a147868b91a51350cc
https://doi.org/10.1158/1078-0432.c.6526496
https://doi.org/10.1158/1078-0432.c.6526496
Autor:
Stephanie Brändlein, Hermann Einsele, Andreas Rosenwald, Frank Hensel, Deanne L. Greenwood, Johannes Düll, Stefan Knop, Manik Chatterjee, Torsten Steinbrunn, Constantin Lapa, Karin Vanderkerken, Eline Menu, Valentina Dubljevic, Emmanuelle Menoret, Leo Rasche
Supplementary Table 1 Figure S1A, S1B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::444864380d01bde967b73cf937a58443
https://doi.org/10.1158/1078-0432.22466978.v1
https://doi.org/10.1158/1078-0432.22466978.v1
Publikováno v:
Therapeutic Advances in Hematology, Vol 12 (2021)
Therapeutic Advances in Hematology
Therapeutic Advances in Hematology
Patients who relapse or are refractory after first-line therapy for diffuse large B-cell lymphoma (DLBCL) frequently have poor prognoses, especially when they are not candidates for autologous stem cell transplant (ASCT). Tafasitamab is a humanized m
Autor:
Denise Grathwohl, Johannes Düll, Leo Rasche, Katharina Nickel, Maximilian Johannes Steinhardt, Martin Kortüm, Sophia Danhof, Xiang Zhou, Katharina Meckel, Andreas Rosenwald, Hans‐Benno Leicht, Franziska Krummenast, Hermann Einsele
We herein report the case of a 73‐year‐old male patient who was diagnosed with leukemic non‐nodal MCL. This patient had received six cycles of bendamustine, which resulted in a transient remission, and a second‐line therapy with ibrutinib, wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a58f1f8dee43546caa379d7fd0a6034
https://opus.bibliothek.uni-wuerzburg.de/files/21551/EJH_EJH13382.pdf
https://opus.bibliothek.uni-wuerzburg.de/files/21551/EJH_EJH13382.pdf
Autor:
Eva González-Barca, Marc André, Pau Abrisqueta, Johannes Weirather, Aleš Obr, Gianluca Gaidano, Kami J. Maddocks, Gilles Salles, Johannes Düll, Wojciech Jurczak, Sumeet Ambarkhane, Tobias Menne, Anna Marina Liberati, Martin Dreyling, Maren Dirnberger-Hertweck
Publikováno v:
Journal of Clinical Oncology. 39:7513-7513
7513 Background: L-MIND (NCT02399085) is an ongoing, open-label, Phase II study of tafasitamab (MOR208), an Fc-modified, humanized, anti-CD19 monoclonal antibody, plus LEN in ASCT-ineligible patients (pts) with R/R DLBCL. Primary analyses and 2-year
Autor:
Deanne L. Greenwood, Andreas Rosenwald, Eline Menu, Constantin Lapa, Valentina Dubljevic, Manik Chatterjee, Hermann Einsele, Stefan Knop, Torsten Steinbrunn, Emmanuelle Menoret, Frank Hensel, Johannes Düll, Leo Rasche, Stephanie Brändlein, Karin Vanderkerken
Purpose: Glucose-regulated protein (GRP) 78 is overexpressed in multiple myeloma, and both its surface expression and its biologic significance as key sensor of the unfolded protein response make GRP78 an ideal candidate for immunotherapeutic interve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63f0d9beec21f5b766cd23c5603de6be
https://hdl.handle.net/20.500.14017/1888a226-44fd-4a6e-be7d-7044e26c42c7
https://hdl.handle.net/20.500.14017/1888a226-44fd-4a6e-be7d-7044e26c42c7
Autor:
Gerd Munzert, Johannes Düll, Hermann Einsele, Edith Gracien, Michel Attal, Benjamin Hebraud, Max S. Topp, Philippe Moreau, Carlos Gomez-Roca, Thierry Facon, Christian Langer, Gerhard Zugmaier
Publikováno v:
Journal of Clinical Oncology. 34:TPS8067-TPS8067
TPS8067Background: Myeloma is an incurable disease that typically follows a relapsing course, with many patients (pts) requiring multiple lines of therapy. Outcomes in RRMM remain poor, particularl...